Key result
Novel mutations exclusive to certain demographics support a shift toward molecularly informed diagnostics for myxofibrosarcoma.
Why the study?
In the era of precision medicine, classifying cancers by molecular markers is increasingly valuable to support a shift beyond histology toward molecularly informed diagnostics and targeted therapies for MFS.
Observational
This genomic analysis of myxofibrosarcoma identifies novel mutations such as NOTCH3 and ALOX12B, supporting a shift toward molecularly informed diagnostics and targeted therapies.
Should not yet inform diagnostics in myxofibrosarcoma; hypothesis-generating for demographic-specific molecular subtypes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nooney et al. (2026) conducted an observational in Myxofibrosarcoma (MFS). Genomic profiling was evaluated. Genomic analysis of myxofibrosarcoma identified novel mutations and demographic-specific mutations, supporting a shift toward molecularly informed diagnostics and targeted therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: